Aviva PLC bought a new stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 103,651 shares of the medical research company's stock, valued at approximately $5,824,000. Aviva PLC owned about 0.06% of Exact Sciences at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Rhenman & Partners Asset Management AB increased its position in shares of Exact Sciences by 1.3% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 471,000 shares of the medical research company's stock worth $26,465,000 after purchasing an additional 6,000 shares in the last quarter. Resona Asset Management Co. Ltd. purchased a new position in Exact Sciences during the 4th quarter worth $3,031,000. Prudential PLC acquired a new position in Exact Sciences during the 4th quarter valued at about $483,000. ExodusPoint Capital Management LP raised its stake in Exact Sciences by 223.4% in the fourth quarter. ExodusPoint Capital Management LP now owns 195,791 shares of the medical research company's stock valued at $11,001,000 after buying an additional 135,245 shares during the last quarter. Finally, Cinctive Capital Management LP raised its stake in Exact Sciences by 1,220.2% in the fourth quarter. Cinctive Capital Management LP now owns 112,351 shares of the medical research company's stock valued at $6,313,000 after buying an additional 103,841 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on EXAS shares. Barclays dropped their price target on Exact Sciences from $65.00 to $55.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Mizuho started coverage on shares of Exact Sciences in a research report on Thursday, April 10th. They set an "outperform" rating and a $60.00 target price on the stock. Guggenheim reaffirmed a "buy" rating and issued a $60.00 price target on shares of Exact Sciences in a report on Friday. Bank of America dropped their price objective on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Finally, Piper Sandler reduced their target price on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Exact Sciences presently has an average rating of "Moderate Buy" and a consensus target price of $69.25.
Read Our Latest Stock Analysis on Exact Sciences
Exact Sciences Stock Performance
NASDAQ EXAS traded down $0.45 during mid-day trading on Tuesday, reaching $43.80. 295,208 shares of the stock were exchanged, compared to its average volume of 2,596,565. The company has a market capitalization of $8.14 billion, a P/E ratio of -7.86 and a beta of 1.14. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. The business's 50 day moving average is $46.72 and its 200-day moving average is $55.57. Exact Sciences Co. has a 1 year low of $39.97 and a 1 year high of $72.83.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The firm had revenue of $713.42 million for the quarter, compared to analysts' expectations of $701.45 million. On average, equities research analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.
Exact Sciences Company Profile
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Further Reading
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
